Doxorubicin conjugated to d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS): Conjugation chemistry, characterization, in vitro and in vivo evaluation

Biomaterials

Volumn 29, Issue 28, 2008, Pages 3856-3865

  Cao, Na ^a   Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cancer chemotherapy; Chemotherapeutic engineering; Drug modification; Polymer drug conjugation; Prodrug

Indexed keywords

CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE; ETHYLENE GLYCOL; GLYCOLS; PHOTOACOUSTIC EFFECT; PHOTORESISTS; POLYETHYLENE GLYCOLS; QUANTUM CHEMISTRY; THERMOPLASTICS;

(R ,S)-CONJUGATE; ANTI CANCER DRUGS; CARRIER (CO); CELLULAR UPTAKE; CELLULAR UPTAKE EFFICIENCY; CONJUGATION CHEMISTRY; DOXORUBICIN (DOX); DRUG RELEASE KINETICS; DRUG-LOADING EFFICIENCY; GLIOMA CELLS; IN VIVO EVALUATION; IN-VITRO; INTRACELLULAR DISTRIBUTION; MCF-7 BREAST CANCER CELLS; SIDE EFFECTS; TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE (TPGS);

CELLS;

DOXORUBICIN; TOCOFERSOLAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CELL STRAIN C6; CELL STRAIN MCF 7; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; GLIOMA CELL; HEART; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH ABSORPTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; MALE; MOLECULAR STRUCTURE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; VITAMIN E;

RATTUS;

EID: 48049091570     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.05.016     Document Type: Article

References (50)

1. Saltzman W.M. Drug delivery: engineering principles for drug therapy (2001), Oxford University Press [chapter 6]
2. Borst P., and Schinkel A.H. What have we learnt thus far from mice with disrupted P-glycoprotein genes?. European Journal of Cancer 32 6 (1996) 985-990
3. Liscovitch M., and Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5 4 (2002) 349-355
4. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Seminars in Cancer Biology 8 3 (1997) 161-170
5. Müller M.B., Keck M.E., Binder E.B., Kresse A.E., Hagemeyer T.P., Landgraf R., et al. ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder. Neuropsychopharmacology 28 11 (2003) 1991-1999
6. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2 1 (2002) 48-58
7. Harris A.L., and Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncologica 31 2 (1992) 205-213
8. Feng S.-S., and Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chemical Engineering Science 58 18 (2003) 4087-4114
9. Feng S.S. Nanoparticles of biodegradable polymers for new concept chemotherapy. Expert Review of Medical Devices 1 1 (2004) 115-125
10. Feng S.S. New-concept chemotherapy by nanoparticles of biodegradable polymers - where are we now?. Nanomedicine 1 3 (2006) 297-309
11. Duncan R. The dawning era of polymer therapeutics. Nature Reviews Drug Discovery 2 5 (2003) 347-360
12. Kopeček J., Kopečková P., Minko T., Lu Z.R., and Peterson C.M. Water soluble polymers in tumor targeted delivery. Journal of Controlled Release 74 1-3 (2001) 147-158
13. Kopeček J., Kopečková P., Minko T., and Lu Z.-R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. European Journal of Pharmaceutics and Biopharmaceutics 50 1 (2000) 61-81
14. Chytil P., Etrych T., Koňák C., Šírová M., Mrkvan T., Říhová B., et al. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification. Journal of Controlled Release 115 1 (2006) 26-36
15. Greenwald R.B., Choe Y.H., McGuire J., and Conover C.D. Effective drug delivery by PEGylated drug conjugates. Advanced Drug Delivery Reviews 55 2 (2003) 217-250
16. Li C., Price J.E., Milas L., Hunter N.R., Ke S., Yu D.-F., et al. Antitumor activity of poly(l-glutamic acid)-pachitaxel on syngeneic and xenografted tumors. Clinical Cancer Research 5 (1999) 891-897
17. Feng X., Yuan Y.J., and Wu J.C. Synthesis and evaluation of water-soluble paclitaxel prodrugs. Bioorganic & Medicinal Chemistry Letters 12 22 (2002) 3301-3303
18. Conover C.D., Greenwald R.B., Pendri A., Gilbert C.W., and Shum K.L. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemotherapy and Pharmacology 52 5 (1998) 407-414
19. Veronese F.M., Schiavon O., Pasut G., Mendichi R., Andersson L., Tsirk A., et al. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjugate Chemistry 16 4 (2005) 775-784
20. Fischer J.R., Harkin K.R., and Freeman L.C. Concurrent administration of water-soluble vitamin E can increase the oral bioavailability of cyclosporine a in healthy dogs. Veterinary Therapeutics: Research in Applied Veterinary Medicine 2002 3 (2002) 465-473
21. Van Rensburg C.E.J., Jooné G., and Anderson R. α-Tocopherol antagonizes the multidrug-resistance-reversal activity of cyclosporin A, verapamil, GF120918, clofazimine and B669. Cancer Letters 127 1-2 (1998) 107-112
22. Fantappiè O., Lodovici M., Fabrizio P., Marchetti S., Fabbroni V., Solazzo M., et al. Vitamin E protects DNA from oxidative damage in human hepatocellular carcinoma cell lines. Free Radical Research 38 7 (2004) 751-759
23. Bogman K., Zysset Y., Degen L., Hopfgartner G., Gutmann H., Alsenz J., et al. P-Glycoprotein and surfactants: effect on intestinal talinolol absorption. Clinical Pharmacology and Therapeutics 77 1 (2005) 24-32
24. Prasad Y.V.R., Puthli S.P., Eaimtrakarn S., Ishida M., Yoshikawa Y., Shibata N., et al. Enhanced intestinal absorption of vancomycin with labrasol and d-α-tocopheryl PEG 1000 succinate in rats. International Journal of Pharmaceutics 250 1 (2003) 181-190
25. Dintaman J.M., and Silverman J.A. Inhibition of P-glycoprotein by d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharmaceutical Research 16 10 (1999) 1550-1556
26. Blum R.H., and Carter S.H. Adriamycin: a new anticancer drug with significant clinical activity. Annals of Internal Medicine 80 (1974) 249-259
27. Al-Shabanah O.A., El-Kashef H.A., Badary O.A., Al-Bekairi A.M., and Elmazar M.M.A. Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. Pharmacological Research 41 1 (2000) 31-37
28. Petit T. Anthracycline-induced cardiotoxicity. Bull Cancer 91 Suppl. 3 (2004) 159-165
29. Krishna R., and Mayer L.D. Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. European Journal of Pharmaceutical Sciences 11 4 (2000) 265-283
30. Hazra B., Golenser J., Nechemiya O., Bhattacharyya S., Azzam T., Domb A., et al. Inhibitory activity of diospyrin derivatives against Leishmania major parasites in vitro. Indian Journal of Pharmacology 34 6 (2002) 422-427
31. Zhang Z., Lee S.H., and Feng S.S. Folate-decorated poly(lactic-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials 28 10 (2007) 1889-1899
32. Watson I.D., Stewart M.J., and Farid Y.Y.Z. The effect of surfactants on the high-performance liquid chromatography of anthracyclines. Journal of Pharmaceutical & Biomedical Analysis 3 6 (1985) 555-563
33. Park K., Lee G.Y., Kim Y.-S., Yu M., Park R.-W., Kim I.-S., et al. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. Journal of Controlled Release 114 3 (2006) 300-306
34. Tomlinson R., Heller J., Brocchini S., and Duncan R. Polyacetal-doxorubicin conjugates designed for pH-dependent degradation. Bioconjugate Chemistry 14 6 (2003) 1096-1106
35. Houba P.H.J., Boven E., Meulen-Muileman I., Leenders R.G.G., Scheeren J.W., Pinedo H.M., et al. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. British Journal of Cancer 84 4 (2001) 550-557
36. Gao Z.G., Lee D.H., Kim D.I., and Bae Y.H. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. Journal of Drug Targeting 13 7 (2005) 391-397
37. Gavenda A., Ševčík J., Psotová J., Bednář P., Barták P., Adamovský P., et al. Determination of anthracycline antibiotics doxorubicin and daunorubicin by capillary electrophoresis with UV absorption detection. Electrophoresis 22 13 (2001) 2782-2785
38. Seymour L.W., Miyamoto Y., Maeda H., Brereton M., Strohalm J., Ulbrich K., et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. European Journal of Cancer 31 5 (1995) 766-770
39. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clinical Cancer Research 5 (1999) 83-94
40. Rodrigues P.C.A., Beyer U., Schumacher P., Roth T., Fiebig H.H., Unger C., et al. Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. Bioorganic & Medicinal Chemistry 7 11 (1999) 2517-2524
41. Hoes C.J.T., Grootoonk J., Duncan R., Hume I.C., Bhakoo M., Bouma J.M.W., et al. Biological properties of adriamycin bound to biodegradable polymeric carriers. Journal of Controlled Release 23 1 (1993) 37-53
42. Maeda H., Seymore L.W., and Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chemistry 3 (1992) 351-362
43. Takakura Y., and Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Critical Reviews in Oncology/Hematology 18 (1995) 207-231
44. Vigevani A., and Williamson M.J. Doxorubicin (1980), Academic Press, New York
45. Zhang Z., and Feng S.-S. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27 21 (2006) 4025-4033
46. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs 3 (1992) 175-210
47. Youk H.J., Lee E., Choi M.K., Lee Y.J., Chung J.H., Kim S.H., et al. Enhanced anticancer efficacy of α-tocopheryl succinate by conjugation with polyethylene glycol. Journal of Controlled Release 107 1 (2005) 43-52
48. Porta C.A.L. Cellular targets for anticancer strategies. Current Drug Targets 5 4 (2004) 347-355
49. Renschler M.F. The emerging role of reactive oxygen species in cancer therapy. European Journal of Cancer 40 13 (2004) 1934-1940
50. Senter P.D., Svensson H.P., Schreiber G.J., Rodriguez J.L., and Vrudhula V.M. Poly(ethylene glycol)-doxorubicin conjugates containing β-lactamase-sensitive linkers. Bioconjugate Chemistry 6 4 (1995) 389-394